Biocryst Pharmaceuticals (BCRX)

Overall impact
C (60)

Commentary

Biocryst Pharmaceuticals is an average overall performer. With a 'C' rating of 60.0 for overall impact (63rd percentile compared to all companies), Biocryst Pharmaceuticals ranks 410th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 406 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 172 others. On top material causes for Biocryst Pharmaceuticals's industry (Pharmaceuticals & Biotech), Biocryst Pharmaceuticals performs well in Child and Maternal Health (82.5 score), Disease Eradication (95.8) and Technology Innovation (90.9) and performs poorly in Humane Treatment of Animals (3.6 score) and Disaster Readiness and Effective Aid (33.0).
Impact
Cause BCRX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
435
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Nc, United States
Share classes
BCRX
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Material causes
Ethos considers the following causes material for Biocryst Pharmaceuticals, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.